Track topics on Twitter Track topics that are important to you
Drug developer Indivior PLC (LON:INDV) has been granted a US Priority Review designation for RBP-6000, its new once-monthly injection for opioid addicts. A priority review means US regulator the Food and Drug Administration will review a new drug application (NDA) within six months instead of the standard ten. The NDA was submitted on May 30 based on data from a Phase 3 study of people addicted to opiods such as heroin, morphine and codeine. "FDA acceptance with a Priority Review designation of our NDA application for RBP-6000 represents a significant milestone for our company as well as for the broader field of opioid use disorder treatment," said Shaun Thaxter, chief executive. "If approved, RBP-6000 would represent the first once-monthly injectable buprenorphine treatment for OUD [opioid use disorder]." The product is intended to be administered by healthcare professionals only, he added. Indivior’s core products currently are the buprenorphine-based opiod abuse treatments Subutex (non-US) and Suboxone, for which it is facing multiple legal actions in the US over its marketing and promotion.
Original Article: Indivior granted US priority review for new monthly addiction treatmentNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...